Home / Filing changes / REGN
Free · no account · quoted from the filing
What changed in REGN's 10-Q
Source: 10-Q filed 2026-04-29 · compared against 10-Q 2025-10-28. Every passage below is quoted verbatim from the filing itself.
Sanofi Collaboration
This filing
The Company co-commercializes Dupixent in the United States and in certain countries outside the United States.
New Approvals and Products
This filing
Approved by U.S. Food and Drug Administration ("FDA") for extension of dosing intervals up to 20 weeks in wAMD and DME
Risk Factors
This filing
changes to drug pricing regulations and requirements and our drug pricing strategy, including in connection with our April 2026 agreements with the U.S. government
What it means — the analyst reading
The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel, plus 3 further changes without a quotable passage — is part of the Filing Change Monitor.
See the Filing Change Monitor →Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.